Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Rating Upgraded by The Goldman Sachs Group

Tarsus Pharmaceuticals (NASDAQ:TARS) was upgraded by The Goldman Sachs Group to a “strong-buy” rating in a report issued on Thursday, Zacks reports.

Several other equities analysts have also issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Friday, July 17th. Mizuho dropped their price objective on Tarsus Pharmaceuticals from $100.00 to $98.00 and set an “outperform” rating on the stock in a research note on Friday, July 31st. Jefferies Financial Group lifted their target price on Tarsus Pharmaceuticals from $88.00 to $105.00 and gave the stock a “buy” rating in a report on Tuesday, September 8th. Barclays began coverage on Tarsus Pharmaceuticals in a research note on Wednesday, September 16th. They issued an “overweight” rating and a $110.00 target price for the company. Finally, Guggenheim lowered their price target on Tarsus Pharmaceuticals from $90.00 to $89.00 and set a “buy” rating for the company in a report on Tuesday, July 21st. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $100.86.

Tarsus Pharmaceuticals Stock Down 0.4%

Tarsus Pharmaceuticals stock opened at $75.69 on Thursday. The firm has a market capitalization of $3.32 billion, a price-to-earnings ratio of -69.44 and a beta of 0.54. The company’s 50 day simple moving average is $71.22 and its 200 day simple moving average is $66.83. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.20 and a quick ratio of 3.17. Tarsus Pharmaceuticals has a fifty-two week low of $53.89 and a fifty-two week high of $91.53.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its earnings results on Thursday, August 6th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.24). The firm had revenue of $173.91 million during the quarter, compared to the consensus estimate of $169.65 million. Tarsus Pharmaceuticals had a negative net margin of 7.67% and a negative return on equity of 13.53%. As a group, sell-side analysts anticipate that Tarsus Pharmaceuticals will post -2.4 EPS for the current year.

Insider Activity

In related news, insider Elizabeth Lin sold 10,773 shares of the company’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $87.50, for a total value of $942,637.50. Following the completion of the transaction, the insider directly owned 2,547 shares of the company’s stock, valued at approximately $222,862.50. This represents a 80.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director William J. Phd Link sold 12,500 shares of the stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $78.38, for a total value of $979,750.00. Following the transaction, the director owned 94,487 shares of the company’s stock, valued at approximately $7,405,891.06. This trade represents a 11.68% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 48,031 shares of company stock worth $4,004,227 over the last quarter. 9.64% of the stock is currently owned by company insiders.

Institutional Trading of Tarsus Pharmaceuticals

A number of institutional investors have recently modified their holdings of TARS. Rockefeller Capital Management L.P. boosted its position in shares of Tarsus Pharmaceuticals by 15.5% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock worth $105,000 after buying an additional 172 shares during the period. Parallel Advisors LLC raised its position in Tarsus Pharmaceuticals by 139.2% in the 1st quarter. Parallel Advisors LLC now owns 500 shares of the company’s stock valued at $35,000 after buying an additional 291 shares during the last quarter. Strs Ohio raised its position in Tarsus Pharmaceuticals by 4.8% in the 1st quarter. Strs Ohio now owns 8,800 shares of the company’s stock valued at $617,000 after buying an additional 400 shares during the last quarter. Swiss National Bank lifted its stake in Tarsus Pharmaceuticals by 0.8% in the 1st quarter. Swiss National Bank now owns 62,933 shares of the company’s stock valued at $4,415,000 after acquiring an additional 500 shares in the last quarter. Finally, PNC Financial Services Group Inc. lifted its stake in Tarsus Pharmaceuticals by 367.1% in the 1st quarter. PNC Financial Services Group Inc. now owns 710 shares of the company’s stock valued at $50,000 after acquiring an additional 558 shares in the last quarter. 90.01% of the stock is currently owned by institutional investors.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a commercial-stage ophthalmic pharmaceutical company focused on developing and marketing treatments for eye conditions with significant unmet medical needs. The company’s lead product is XDEMVY (lotilaner ophthalmic solution) 0.25%, a prescription eye drop approved by the U.S. Food and Drug Administration in 2023 for the treatment of Demodex blepharitis, a common eyelid disorder associated with an infestation of Demodex mites.

XDEMVY is designed to target and eliminate Demodex mites, addressing an underlying cause of the disease rather than only managing its symptoms.